Furthermore, low expression or inhibition of MFN1, as well as upregulation of Drp1, enhance this phenotype in metastatic breast cancer 51, colorectal cancer cells 40, lung cancer 52, melanoma 53, glioblastoma 54, pancreatic cancers 55, and neuroblastoma 56. This evidence concerns the gene DNM1L and familial pancreatic carcinoma.